The decision came after a scorching hearing in which lawmakers barraged EcoHealth Allianceβs president with claims of misrepresenting work with Chinese virologists.
Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.